Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
In wrangling dark matter, some scientists find inspiration in the Torah, Krishna and Christ - 2Opening Your True capacity: 12 Techniques for Personal growth
- 3The Following Huge Thing: 5 Progressive Tech New businesses
- 4Building an Individual Brand: Illustrations from Forces to be reckoned with
- 5Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- 4 Must-Visit bar-b-que Eateries This Year
- Lift Your Style: Famous Hairdos for Ladies
- Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- South African radio presenter among five charged over Russia recruitment plot
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- Flu season is ramping up, and some experts are "pretty worried"
- Manual for Picking Coastline Travel
- A Manual for the Right SUV for Seniors
